Toxoplasmosis Treatment Drugs Market by Drug Class, by Indication, by Route of Administration, by Distribution Channel, and By Region

PUBLISHED: March 25, 2025

PAGES: 250 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Toxoplasmosis Treatment Drugs Market is estimated to be valued at USD 3,670.1 Mn in 2025 and is expected to reach USD 5,268.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 3,670.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.30%	2032 Value Projection:	USD 5,268.4 Mn

Toxoplasmosis is an infection caused by a parasite called Toxoplasma gondii. Currently recommended toxoplasmosis drugs target the tachyzoite stage of the parasite and do not remove the parasite from the tissues. Pyrimethamine is considered the most effective anti-toxoplasmosis drug, and it is a standard component of treatment. Pyrimethamine is a folic acid antagonist and can cause dose-dependent bone marrow suppression, which is alleviated by the concomitant administration of folic acid (leucovorin). Leucovorin protects the bone marrow from the toxic effects of pyrimethamine. If the patient experiences a hypersensitive reaction to sulfa medications, another medication, such as sulfadiazine or clindamycin, should be added. As an alternative, a fixed combination of trimethoprim with sulfamethoxazole and other drugs such as atovaquone and pyrimethamine and azithromycin are used for toxoplasmosis treatment.

Market Dynamics

Medicines are used to treat active infections. These factors include the severity of your illness, the state of your immune system, and the location of the infection. Another aspect is pregnancy's stage. For example, on November 3, 2022, a U.S.-based hospital, Mayo Clinics published an article explaining pyrimethamine (Daraprim), which fights against infections caused by microscopic organisms. It can block the body's use of folic acid. Other possible side effects of its long-term use include bone marrow suppression and liver toxicity. Leucovorin calcium helps correct the effect of pyrimethamine on folic acid. Sulfadiazine is an antibiotic often prescribed with pyrimethamine. Other medications include clindamycin (Cleocin), azithromycin (Zithromax), and others. To diagnose toxoplasmosis in a newborn baby, blood tests are prescribed if infection is suspected. A baby with a positive test result will undergo many tests to identify and monitor the disease.

Key features of the study:

This report provides an in-depth analysis of the global toxoplasmosis treatment drugs market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global toxoplasmosis treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd, Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market

Detailed Segmentation:

Global Toxoplasmosis Treatment Drugs Market, By Drug Class
- Pyrimethamine
- Spiramycin
- Leucovorin
- Sulfadiazine
- Folic Acid
- Others
Global Toxoplasmosis Treatment Drugs Market, By Indication:
- Chronic Toxoplasmosis Infection
- Acute Toxoplasmosis Infection
Global Toxoplasmosis Treatment Drugs Market, By Route of administration:
- Parenteral
- Oral
Global Toxoplasmosis Treatment Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Global Toxoplasmosis Treatment Drugs Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Company Profiles
- Vyera Pharmaceuticals LLC
- Taj Accura Pharmaceuticals Ltd
- Mangalam Drugs and Organics Ltd
- Cerovene Healthcare PVT LTD
- Greenstone LLC
- Amneal Pharmaceuticals, Inc.
- Turing Pharmaceuticals
- F.Hoffmann-La Roche AG
- Teva Pharmaceutical Industries Ltd
- Baxter International Inc

Product Code: CMI4166

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Indication
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Toxoplasmosis Treatment Drugs Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Toxoplasmosis Treatment Drugs Market, by Drug Class, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Pyrimethamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Spiramycin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Leucovorin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Sulfadiazine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Folic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Toxoplasmosis Treatment Drugs Market, By Indication, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Chronic Toxoplasmosis Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Acute Toxoplasmosis Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Toxoplasmosis Treatment Drugs Market, by Route of Administration, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

8. Global Toxoplasmosis Treatment Drugs Market, by Distribution Channel, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

9. Global Toxoplasmosis Treatment Drugs Market, By Region, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Vyera Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Taj Accura Pharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mangalam Drugs and Organics Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cerovene Healthcare PVT LTD
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Greenstone LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amneal Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Turing Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries Ltd
Baxter International Inc